SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

USFDA completes Lupin’s Goa facility inspection without any observations

22 Jul 2017 Evaluate

US Food and Drug Administration (USFDA) has successfully completed Prior Approval Inspection (PAI) at Lupin’s Goa manufacturing facility without any observations. The inspection which started on July 17 concluded on July 21, 2017.

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.

Lupin Share Price

2243.45 -134.45 (-5.65%)
11-May-2026 09:48 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1845.75
Dr. Reddys Lab 1275.50
Cipla 1333.75
Zydus Lifesciences 934.50
Lupin 2243.45
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×